Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From OptiNose, Inc.
Finance Watch: CG Oncology, MBX, Jnana Bring In VC Mega-Rounds
Private Company Edition: In the latest round of $100m-plus venture capital financings, CG Oncology, MBX Biosciences and Jnana Therapeutics raised $120m, $115m and $107m, respectively. Also, MVM Partners closed a $500m fund and former Sage CEO leads incubator ABio-X in Massachusetts.
Optinose Looking For A Partner To Optimize Big Opportunity In Chronic Sinusitis
With positive Phase III data for its Xhance (fluticasone propionate) nasal spray in chronic sinusitis, Optinose believes it is poised to expand the target market for the drug 10-fold.
Keeping Track: Vascepa Adds CV Risk Reduction Claim And Submissions Pour Into FDA
The latest drug development news and highlights from our US FDA Performance Tracker.
Finance Watch: Big Money For Big Goals Met By Reata, CRISPR, Karuna
Public Company Edition: Also, Teva sells $2.1bn in notes to pay prior debts. In restructurings, Baudax splits off from Recro, while three firms shift their focus to specific cell therapy programs.
- Medical Devices
- Drug Delivery
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- OptiNose AS
- OptiNose UK Ltd.
- OptiNose US, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.